Compare Nucor Corporation (NUE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Nucor Corporation trades at $230.8 (market cap $52.55B), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Nucor Corporation pays the higher dividend (0.97%). Which is the better fit depends on your goals.
| NUE | REGN | |
|---|---|---|
Market Cap | $52.55B | $70.47B |
Sector | Basic Materials | Health |
52-Week High | $266.35 | $812.27 |
52-Week Low | $131.78 | $545.46 |
Enterprise Value | $57.19B | $64.42B |
Dividend Yield | 0.97% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $233.2, down 1.44% over 24 hours, with technical indicators showing a bearish trend near key support at $228. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has stabilized around $32.5B in 2025 after declines from 2022 peaks, while net margins compressed to 5.36%. Analyst sentiment remains positive with a 62.5% buy rating and $263.11 consensus target, supported by strong cash flow and a 53-year dividend growth streak.
NUE offers value with reasonable valuation multiples (P/E 22.89, P/S 1.55) and robust shareholder returns, but faces risks from steel demand volatility and margin pressure. The upcoming Q2 earnings report on July 27, 2026, will be critical for confirming growth trajectory amid economic uncertainties.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
